ӳ��ý

Publications

Tracking rare single donor and recipient immune and leukemia cells after allogeneic hematopoietic cell transplantation using mitochondrial DNA mutations.

Penter L, Cieri N, Maurer K, et al. Tracking rare single donor and recipient immune and leukemia cells after allogeneic hematopoietic cell transplantation using mitochondrial DNA mutations. Blood cancer discovery. 2024. doi:10.1158/2643-3230.BCD-23-0138

CDK5-cyclin B1 regulates mitotic fidelity.

Zheng XF, Sarkar A, Lotana H, et al. CDK5-cyclin B1 regulates mitotic fidelity. Nature. 2024. doi:10.1038/s41586-024-07888-x

A pathology foundation model for cancer diagnosis and prognosis prediction.

Wang X, Zhao J, Marostica E, et al. A pathology foundation model for cancer diagnosis and prognosis prediction. Nature. 2024. doi:10.1038/s41586-024-07894-z

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.

Liu I, Cruzeiro GAV, Bjerke L, et al. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. Cancer cell. 2024. doi:10.1016/j.ccell.2024.08.006

CDK5-cyclin B1 regulates mitotic fidelity.

Zheng XF, Sarkar A, Lotana H, et al. CDK5-cyclin B1 regulates mitotic fidelity. Nature. 2024. doi:10.1038/s41586-024-07888-x

A pathology foundation model for cancer diagnosis and prognosis prediction.

Wang X, Zhao J, Marostica E, et al. A pathology foundation model for cancer diagnosis and prognosis prediction. Nature. 2024. doi:10.1038/s41586-024-07894-z

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.

Liu I, Cruzeiro GAV, Bjerke L, et al. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. Cancer cell. 2024. doi:10.1016/j.ccell.2024.08.006

Author Correction: A benchmark of computational methods for correcting biases of established and unknown origin in CRISPR-Cas9 screening data.

Vinceti A, Iannuzzi RM, Boyle I, et al. Author Correction: A benchmark of computational methods for correcting biases of established and unknown origin in CRISPR-Cas9 screening data. Genome biology. 2024;25(1):239. doi:10.1186/s13059-024-03387-4

Targeting the Tie-2 Receptor with Faricimab in Central Serous Chorioretinopathy: A Case Series Motivated by a Genetic Finding: Faricimab in central serous chorioretinopathy.

Rämö JT, Kim LA, Stryjewski T, et al. Targeting the Tie-2 Receptor with Faricimab in Central Serous Chorioretinopathy: A Case Series Motivated by a Genetic Finding: Faricimab in central serous chorioretinopathy. American journal of ophthalmology. 2024. doi:10.1016/j.ajo.2024.08.040

Integration of observational and causal evidence for the association between adiposity and 17 gastrointestinal outcomes: An umbrella review and meta-analysis.

Kim MS, Lee I, Natarajan P, et al. Integration of observational and causal evidence for the association between adiposity and 17 gastrointestinal outcomes: An umbrella review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2024:e13823. doi:10.1111/obr.13823